{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT00404989",
            "nctIdAliases": [
                "NCT01137981"
            ],
            "orgStudyIdInfo": {
                "id": "APR"
            },
            "organization": {
                "fullName": "Syneos Health",
                "class": "OTHER"
            },
            "briefTitle": "Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women.",
            "officialTitle": "Antiretroviral Pregnancy Registry",
            "acronym": "APR",
            "therapeuticArea": [
                "Infectious Diseases",
                "Gastroenterology"
            ],
            "study": "antiretroviral-pregnancy-registry-apr-multi-sponsor-registry-to-detect-any-major-teratogenic-effect-involving-any-of-the-registry-drugs-when-administered-to-pregnant-women"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "1989-01"
            },
            "primaryCompletionDateStruct": {
                "date": "2099-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2099-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2006-11-27",
            "studyFirstSubmitQcDate": "2006-11-28",
            "studyFirstPostDateStruct": {
                "date": "2006-11-29",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2024-06-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-14",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Syneos Health",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "AbbVie",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Alvogen Korea",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Amneal Pharmaceuticals, LLC",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Apotex Inc.",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Boehringer Ingelheim",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Bristol-Myers Squibb",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Cipla Ltd.",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Dr. Reddy's Laboratories Limited",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Gilead Sciences",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Hetero Labs",
                    "class": "UNKNOWN"
                },
                {
                    "name": "Hikma Pharmaceuticals LLC",
                    "class": "INDUSTRY"
                },
                {
                    "name": "i3 Pharmaceuticals, LLC",
                    "class": "UNKNOWN"
                },
                {
                    "name": "Janssen Scientific Affairs, LLC",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Lannett Company, Inc.",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Laurus Labs Limited",
                    "class": "UNKNOWN"
                },
                {
                    "name": "Lupin Pharmaceuticals, Inc.",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Macleods Pharmaceuticals Ltd",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Merck Sharp & Dohme LLC",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Mylan Laboratories",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Pharmascience Inc.",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Qilu Pharmaceutical Co., Ltd.",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Sigmapharm Laboratories",
                    "class": "UNKNOWN"
                },
                {
                    "name": "Strides Shasun Limited",
                    "class": "UNKNOWN"
                },
                {
                    "name": "Teva Pharmaceuticals USA",
                    "class": "INDUSTRY"
                },
                {
                    "name": "ViiV Healthcare",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true
        },
        "descriptionModule": {
            "briefSummary": "The purpose of the Antiretroviral Pregnancy Registry (Registry) is to detect any major teratogenic effect involving any of the Registry drugs when administered to pregnant women. Registration is voluntary and confidential with information obtained from the health care provider. A Registry-assigned identifier allows for follow-up capability. Information on subjects is provided to the Registry prospectively (prior to the outcome of pregnancy being known) through their health care provider, with follow-up obtained from the health care provider after the outcome is determined. Providers are strongly urged to enroll their patients as early in pregnancy as possible to maximize the validity of the data. In addition, the Registry is very interested in assembling a group of providers who are willing to make a commitment to report all of their site's antiretroviral pregnancy exposures to the Registry, thereby assuring all cases can be considered prospective. Providers are encouraged to contact the Registry for more information about this group. The Registry is informed in its analysis by other data, for example, retrospective reports and clinical studies.\n\nGiven the increasing number of medications and more aggressive approach to therapy, more HIV- and hepatitis B-infected women may be treated during pregnancy or become pregnant while under treatment. The paucity of data on use and infant outcomes of antiretroviral therapies during pregnancy makes this Registry an essential component of the ongoing program of epidemiologic studies of the safety of these therapies.\n\nEach year the Registry has enrolled approximately 1300-1700 pregnant women in the US exposed to antiretroviral drugs. This number represents approximately 15% of the 8,700 HIV positive women who give birth to live infants annually in the US.",
            "detailedDescription": "The following antiretroviral drugs are followed by the Antiretroviral Pregnancy Registry (APR, Registry) to detect any major teratogenic effect when administered to pregnant women: abacavir (ZIAGEN\u00ae, ABC), abacavir/lamivudine (EPZICOM\u00ae, KIVEXA\u00ae, EPZ), abacavir/lamivudine/zidovudine (TRIZIVIR\u00ae, TZV), abacavir/dolutegravir/lamivudine (TRIUMEQ\u00ae, TRI), adefovir dipivoxil (HEPSERA\u00ae, ADV), amprenavir (AGENERASE\u00ae, APV), atazanavir (REYATAZ\u00ae, ATV), atazanavir/cobicistat (EVOTAZ\u00ae, EVO), bictegravir/emtricitabine/tenofovir alafenamide (BIKTARVY\u00ae, B/F/TAF), cabotegravir (VOCABRIA\u00ae, CABENUVA\u00ae, APRETUDE\u00ae, CAB), cobicistat (TYBOST\u00ae, COBI), darunavir (PREZISTA\u00ae, DRV), darunavir/cobicistat (PREZCOBIX\u2122, REZOLSTA\u2122, PCX), darunavir/cobicistat/emtricitabine/tenofovir alafenamide (SYMTUZA\u00ae, DCF TAF ), delavirdine mesylate (RESCRIPTOR\u00ae, DLV), didanosine (VIDEX\u00ae, VIDEX\u00ae EC, ddI), dolutegravir (TIVICAY\u00ae, DTG), dolutegravir/lamivudine (DOVATO\u00ae, DTG/RPV), dolutegravir/lamivudine/tenofovir disoproxil fumarate (ACRIPTEGA/TELADOMYL/TENDOLA, TLD), dolutegravir/rilpivirine (JULUCA\u2122, DTG/RPV), emtricitabine/tenofovir alafenamide (DESCOVY\u00ae, DVY), efavirenz (SUSTIVA\u00ae, STOCRIN\u00ae, EFV), efavirenz/emtricitabine/tenofovir disoproxil (ATRIPLA\u00ae ATR), efavirenz/lamivudine/tenofovir disoproxil fumarate (SYMFI\u2122/SYMFI LO\u2122, EFV/3TC/TDF), elvitegravir (VITEKTA\u00ae, EVG), elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (GENVOYA\u00ae, GEN), elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (STRIBILD\u00ae, STB), emtricitabine (EMTRIVA\u00ae, FTC), enfuvirtide (FUZEON\u00ae, T-20), entecavir (BARACLUDE\u00ae, ETV), etravirine (INTELENCE\u00ae, ETR), fosamprenavir calcium (LEXIVA\u00ae, FOS), fostemsavir (RUKOBIA, FTR), indinavir (CRIXIVAN\u00ae, IDV), lamivudine (EPIVIR\u00ae, 3TC), lamivudine/raltegravir (DUTREBIS\u2122, DUT), lamivudine/tenofovir disoproxil fumarate (CIMDUO\u2122, 3TC/TDF), lamivudine/zidovudine (COMBIVIR\u00ae, CBV), lenacapavir (SUNLENCA, LEN) lopinavir/ritonavir (KALETRA\u00ae, ALUVIA\u00ae, LPV/r), maraviroc (SELZENTRY\u00ae, CELSENTRI\u00ae, MVC), nelfinavir (VIRACEPT\u00ae, NFV), nevirapine (VIRAMUNE\u00ae, VIRAMUNE\u00ae XR\u2122, NVP), raltegravir (ISENTRESS\u00ae, RAL), rilpivirine (EDURANT\u00ae, REKAMBYS\u00ae, CABENUVA\u00ae, RPV), rilpivirine/emtricitabine/tenofovir alafenamide (ODEFSEY\u00ae,ODE), rilpivirine/emtricitabine/tenofovir disoproxil (COMPLERA\u00ae, CPA; EVIPLERA\u00ae, EPA), ritonavir (NORVIR\u00ae, RTV), saquinavir (FORTOVASE\u00ae, SQV-SGC), saquinavir mesylate (INVIRASE\u00ae, SQV-HGC), stavudine (ZERIT\u00ae, d4T), telbivudine (SEBIVO\u00ae, TYZEKA\u00ae, LdT), tenofovir alafenamide (VEMLIDY\u00ae, TAF), tenofovir disoproxil fumarate (VIREAD\u00ae, TDF), tenofovir disoproxil fumarate/emtricitabine (TRUVADA\u00ae, TVD), tipranavir (APTIVUS\u00ae, TPV), zalcitabine (HIVID\u00ae, ddC), and zidovudine (RETROVIR\u00ae, ZDV)."
        },
        "conditionsModule": {
            "conditions": [
                "HIV Infections",
                "Hepatitis B"
            ],
            "keywords": [
                "HIV",
                "HBV",
                "Hepatitis",
                "Pregnancy",
                "Registry"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 24258,
                "type": "ESTIMATED"
            }
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Eligibility Ages Eligible for Study: Women of childbearing age\n\nInclusion Criteria:\n\n* Country of origin of report\n* Documentation that the registry drug was taken during pregnancy\n* Sufficient information to determine if the pregnancy is being prospectively or retrospectively registered\n* Date the pregnancy was registered\n* Source of report (patient or health care provider)\n* Whether the pregnancy outcome is already known or delivery is still pending\n* Timing of the prenatal exposure to the registry medication (no broader than which trimester)\n* Sufficient patient identifier relevant to reporter to allow for follow-up\n* Was patient involved in a study at the time of prenatal exposure\n* Full reporter contact information (name, address, etc.)\n\nExclusion Criteria:\n\n* Females who were not exposed to registry medications during pregnancy\n* Male patients",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "minimumAge": "12 Years",
            "maximumAge": "60 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ],
            "studyPopulation": "Pregnant women exposed to antiviral medications during pregnancy.",
            "samplingMethod": "PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Taylor Cook",
                    "role": "CONTACT",
                    "phone": "800-258-4263",
                    "email": "SM_APR@APRegistry.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jessica D Albano, PhD, MPH",
                    "affiliation": "Syneos Health",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Registry Coordinating Center",
                    "status": "RECRUITING",
                    "city": "Wilmington",
                    "state": "North Carolina",
                    "zip": "28403",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.22573,
                        "lon": -77.94471
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "26687320",
                    "type": "DERIVED",
                    "citation": "Vannappagari V, Albano JD, Koram N, Tilson H, Scheuerle AE, Napier MD. Prenatal exposure to zidovudine and risk for ventricular septal defects and congenital heart defects: data from the Antiretroviral Pregnancy Registry. Eur J Obstet Gynecol Reprod Biol. 2016 Feb;197:6-10. doi: 10.1016/j.ejogrb.2015.11.015. Epub 2015 Nov 24."
                },
                {
                    "pmid": "26269220",
                    "type": "DERIVED",
                    "citation": "Vannappagari V, Koram N, Albano J, Tilson H, Gee C. Association between in utero zidovudine exposure and nondefect adverse birth outcomes: analysis of prospectively collected data from the Antiretroviral Pregnancy Registry. BJOG. 2016 May;123(6):910-6. doi: 10.1111/1471-0528.13542. Epub 2015 Aug 12."
                }
            ],
            "seeAlsoLinks": [
                {
                    "label": "Download: data forms to register patients, Semi-Annual Interim Report, product package inserts, organizational links, guidelines, bibliography",
                    "url": "http://apregistry.com"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006509",
                    "term": "Hepatitis B"
                },
                {
                    "id": "D000006505",
                    "term": "Hepatitis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000006525",
                    "term": "Hepatitis, Viral, Human"
                },
                {
                    "id": "D000014777",
                    "term": "Virus Diseases"
                },
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000086982",
                    "term": "Blood-Borne Infections"
                },
                {
                    "id": "D000003141",
                    "term": "Communicable Diseases"
                },
                {
                    "id": "D000018347",
                    "term": "Hepadnaviridae Infections"
                },
                {
                    "id": "D000004266",
                    "term": "DNA Virus Infections"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3522",
                    "name": "Acquired Immunodeficiency Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M18250",
                    "name": "HIV Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M9592",
                    "name": "Hepatitis A",
                    "relevance": "LOW"
                },
                {
                    "id": "M9595",
                    "name": "Hepatitis B",
                    "asFound": "Hepatitis B",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9591",
                    "name": "Hepatitis",
                    "asFound": "Hepatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M30394",
                    "name": "Teratogenesis",
                    "relevance": "LOW"
                },
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9610",
                    "name": "Hepatitis, Viral, Human",
                    "relevance": "LOW"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2593",
                    "name": "Blood-Borne Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M20487",
                    "name": "Hepadnaviridae Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M7442",
                    "name": "DNA Virus Infections",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M25428",
                    "name": "Anti-Retroviral Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}